Arthralgia Global Market Report 2025

The arthralgia market size has grown strongly in recent years. It will grow from $5.2 billion in 2024 to $5.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing incidence of various associated risk factors, the growing rates of obesity, the higher prevalence of arthralgia, and the increasing occurrence of joint disorders.

The arthralgia market size is expected to see strong growth in the next few years. It will grow to $7.73 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period is expected to be driven by increasing awareness of arthralgia, a growing geriatric population, expanding healthcare infrastructure, rising demand for minimally invasive treatments, and the increasing prevalence of sports injuries. Key trends during this period include the integration of digital health solutions, the development of novel therapies and cell therapies, advancements in medical technology, and increased investment in research and development.

The increasing incidence of rheumatoid arthritis is expected to drive the growth of the arthralgia market in the coming years. Rheumatoid arthritis is a chronic autoimmune condition that primarily impacts the joints, causing inflammation, pain, and potential joint damage. The rise in rheumatoid arthritis cases can be attributed to factors such as an aging population, genetic predisposition, lifestyle changes, and environmental factors such as smoking and pollution. Rheumatoid arthritis contributes to arthralgia by causing chronic joint inflammation, leading to pain, stiffness, and progressive damage. For example, in February 2024, Arthritis Australia, a non-profit organization based in Australia, projected that by 2040, arthritis cases in Australia would increase to 5.39 million from 4.11 million in 2025, with rheumatoid arthritis cases reaching 748,721. Consequently, the growing number of rheumatoid arthritis cases is fueling the expansion of the arthralgia market.

Companies in the arthralgia market are focusing on developing innovative treatments, such as RMAT-designated gene therapies, to provide long-term pain relief and improved joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which accelerates the development and review of gene therapies for serious or life-threatening conditions. In March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, received RMAT designation for its product PCRX-201 (enekinragene inzadenovec) from the U.S. Food and Drug Administration (FDA). PCRX-201 is an innovative intra-articular gene therapy candidate designed to treat knee osteoarthritis using a helper-dependent adenovirus (HDAd) to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira emphasized the promising preliminary clinical results, suggesting that PCRX-201 could become a potential disease-modifying treatment for osteoarthritis.

In November 2023, Nevro Corp., a US-based medical device company, acquired Vyrsa Technologies for $75 million. This acquisition allows Nevro to expand its chronic pain treatment portfolio by incorporating Vyrsa Technologies’ minimally invasive SI joint fusion devices. By enhancing its market presence, Nevro aims to provide advanced solutions for long-term pain relief to patients suffering from chronic sacroiliac (SI) joint pain. Vyrsa Technologies, a US-based company, specializes in treating arthralgia, specifically addressing chronic SI joint pain.

Major players in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation, and Vitazan Herbs and Vitamins Inc.

North America was the largest region in the arthralgia market in 2024. The regions covered in arthralgia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the arthralgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Arthralgia refers to pain in one or more joints, usually without inflammation, and can stem from various causes, including infections, autoimmune diseases, or injuries. It is a symptom rather than a standalone condition, often indicating an underlying health issue affecting the joints.

The primary causes of arthralgia include osteoarthritis, rheumatoid arthritis, gout, psoriatic arthritis, lupus, injuries, infections, and other contributing factors. Osteoarthritis is a degenerative joint disease that develops when the protective cartilage cushioning the ends of bones gradually wears down. A range of treatment options is available, including medications, therapies, surgical interventions, and lifestyle or home remedies. These treatments can be administered through different methods, such as oral, injectable, topical, and transdermal routes. They are distributed via hospital pharmacies, retail pharmacies, and online pharmacies and are used across various settings, including hospitals, clinics, home care environments, and rehabilitation centers.

The arthralgia market research report is one of a series of new reports that provides arthralgia market statistics, including the arthralgia industry global market size, regional shares, competitors with the arthralgia market share, detailed arthralgia market segments, market trends, and opportunities, and any further data you may need to thrive in the arthralgia industry. This arthralgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The arthralgia market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, physical rehabilitation programs, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The arthralgia market also includes sales of musculoskeletal diagnostic tools, biologic drugs, anti-inflammatory drugs, and regenerative therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.